There are five companies making Favipiravir now — and it is good for supply and prices

• Favipiravir has demonstrated positive clinical outcomes in some trials and has already been approved for use to treat Covid-19 in Russia and parts of the Middle East.
  
• Sun Pharmaceutical on August 4 announced the launch of Favipiravir, under brand name FluGuard, at ₹35 per tablet for the treatment of mild to moderate cases of Covid-19 in India.
  
• Whereas, Hyderabad-based Zenara Pharma on August 5 announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and sell Favipiravir tablets to treat coronavirus.
  

After Glenmark and Cipla, two more Indian pharma companies — Sun Pharmaceuticals and Zendara Pharma — said they are manufacturing Favipiravir in the country to treat coronavirus.

Favipiravir was originally developed to treat novel influenza in Japan and was sold by different manufacturers under the name Avigan, Abigan and Fabiflu.

Sun Pharmaceuticals on August 4 announced the launch of Favipiravir, under brand name FluGuard, at ₹35 per tablet for the treatment of mild to moderate cases of Covid-19 in India. The stocks of FluGuard will be available in the market from this week.

"We are launching FluGuard at an economical price to make the drug accessible to more and more patients, thereby reducing their financial burden. This is in line with our continuous efforts to support India's pandemic response," Sun Pharma said.

Several other companies have launched the generic versions of Favipiravir so far in India.

Companies which launched Favipiravir	Price
Hetero	₹59 per tablet
Cipla	₹68 per tablet
Glenmark	₹75 per tablet.
Sun Pharmaceutical Industries	₹35 per tablet

Hyderabad-based Zenara Pharma on August 5 announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of Covid-19.

The tablet, which will be sold under the brand name 'Favizen', is being manufactured at Zenara's US FDA approved state-of-the-art facility in Hyderabad.

Zara Pharma, a fully-owned subsidiary of Biophore India Pharmaceuticals, is in talks with multiple state institutions and several hospitals in India to ensure that Favizen is readily available for the patients in need.

Favipiravir has demonstrated positive clinical outcomes in some trials and has already been approved for use to treat Covid-19 in Russia and parts of the Middle East. Advance stage trials are currently underway in several countries, including India.

(With inputs from IANS and PTI)
SEE ALSO:
‘Watchful’ RBI leaves repo rate unchanged to keep inflation in check
The Beirut explosion created a huge mushroom cloud and visible blast wave, but nuclear weapons experts say it wasn't an atomic bomb. Here's why.
Microsoft for Startups’ Lathika Pai says entrepreneurs pitching for investments need to have this one question answered in their pitch decks
LinkedIn, TCS, Disney+ Hotstar, Zee and other companies hiring right now in India